Breakthrough cancer pain - Still a challenge

Journal of Pain Research

Volumn 5, Issue , 2012, Pages 559-566

  Margarit, Cesar ^a   Juliá, Joaquim ^b   López, Rafael ^c   Anton, Antonio ^d   Escobar, Yolanda ^e   Casas, Ana ^f   Cruz, Juan Jesús ^g   Galvez, Rafael ^h   Mañas, Ana ⁱ   Zaragozá, Francisco ^j  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^g Hospital de Salamanca   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^j UNIVERSITY OF ALCALÁ   (Spain)

more..

Author keywords

Diagnosis; Management; Opioids; Prevalence

Indexed keywords

FENTANYL; FENTANYL CITRATE; MORPHINE; NARCOTIC ANALGESIC AGENT;

ARTICLE; BREAKTHROUGH PAIN; CANCER PAIN; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; EPIDEMIOLOGICAL DATA; HUMAN; MANAGED CARE; PAIN ASSESSMENT; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84874961639     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S36428     Document Type: Article

References (40)

1. WHO Expert Committee. Cancer Pain Relief. Geneva: World Health Organization; 1986.
2. Reyes Chiquete D, González Ortiz JC, Mohar Betancourt A, Meneses García A. Epidemiología del dolor por cancer [Epidemiology of cancer pain]. Rev Soc Esp Dolor. 2011;18(2):118-134. Spanish.
3. Breivik H, Cherny N, Collett B, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20(8):1420-1433.
4. Yang P, Cheville AL, Wampfler JA, et al. Quality of life and symptom burden among long-term lung cancer survivors. J Thorac Oncol. 2012; 7(1):64-70.
5. González-Escalada JR, Camba A, Casas A, et al. Código de buena práctica para el control del dolor oncológico [Good practice code for the management of cancer pain]. Rev Soc Esp Dolor. 2011;18(2):98-117. Spanish.
6. Ministerio de Sanidad y Consumo de España. Estrategia en Cáncer del Sistema Nacional de Salud. Madrid: Ministerio de Sanidad y Consumo de España; 2006. Spanish. Available from: http://www.msps.es/organizacion/sns/planCalidadSNS/pdf/ActualizacionEstrategiaCancer.pdf. Accessed September 28, 2012.
7. Palesh OG, Collie K, Batiuchok D, et al. A longitudinal study of depression, pain, and stress as predictors of sleep disturbance among women with metastatic breast cancer. Biol Psychol. 2007;75(1):37-44.
8. Scharpf J, Karnell LH, Christensen AJ, Funk GF. The role of pain in head and neck cancer recurrence and survivorship. Arch Otolaryngol Head Neck Surg. 2009;135(8):789-794.
9. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41(3):273-281.
10. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81(1-2):129-134.
11. Zeppetella G. Breakthrough pain should be distinguished from background pain. Guidelines in Practice. 2009;12(3):1-6.
12. Caraceni A, Martini C, Zecca E, et al; Working Group of an IASP Task Force on Cancer Pain. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18(3):177-183.
13. Zeppetella G. Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care. 2009;3(1):1-6.
14. Davies AN. The management of breakthrough cancer pain. Br J Nurs. 2011:20(13):803-807.
15. Dickman A. Integrated strategies for the successful management of breakthrough cancer pain. Curr Opin Support Palliat Care. 2011; 5(1):8-14.
16. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G; Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13(4):331-338.
17. Porta-Sales J, Garzón Rodríguez C, Julià Torras J, Casals Merchán M. Dolor irruptivo en cáncer [Cancer-related breakthrough pain]. Med Clin (Barc). 2010;135(6):280-285. Spanish.
18. Swanwick M, Haworth M, Lennard RF. The prevalence of episodic pain in cancer: a survey of hospice patients on admission. Palliat Med. 2001;15(1):9-18.
19. Davies A, Zeppetella G, Andersen S, et al. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain. 2011;15(7): 756-763.
20. American Pain Foundation. Breakthrough cancer pain: mending the break in the continuum of care. J Pain Palliat Care Pharmacother. 2011;25(3):252-264.
21. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain. 2005;9(2):195-206.
22. Howell J, Dumble S. Quality of life in patients with breaththrough cancer pain: results from the two phase III studies of sublingual fentanyl. European Journal of Pain Supplements. 2011;5:171. doi 10.1016/S1754-3207(11)70588-0.
23. Breuer B, Fleishman SB, Cruciani RA, Portenoy RK. Medical oncologists' attitudes and practice in cancer pain management: a national survey. J Clin Oncol. 2011;29(36):4769-4775.
24. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9): 1437-1449.
25. Bernabei R, Gambassi G, Lapane K, et al. Management of pain in elderly patients with cancer. SAGE Study Group. Systematic Assessment of Geriatric Drug Use via Epidemiology. JAMA. 1998;279(23):1877-1882.
26. Gómez-Batiste X, Madrid F, Moreno F, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage. 2002;24(1):45-52.
27. Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain. 2002;3(1):38-44.
28. American Pain Foundation. Breakthrough Cancer Pain Survey Fact Sheet. American Pain Foundation; 2012. Available from: http://nci.nih.gov/dictionary/?CdrID=45612. Accessed June 12, 2012.
29. Von Roenn JH, Cleeland CS, Gonin R, Hatfield AK, Pandya KJ. Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med. 1993;119(2):121-126.
30. Carulla Torrent J, Jara Sánchez C, Sanz Ortiz J, el al; ALGOS Group. Oncologists' perceptions of cancer pain management in Spain: the real and the ideal. Eur J Pain. 2007;11(3):352-359.
31. Escobar Álvarez Y, Rodríguez Sánchez C, Caballero Martínez F, Recuero Cuervo V, Camps Herrero C. Professional survey on knowledge and clinical patterns of pain management in Spanish medical oncology. Clin Transl Oncol. 2010;12(12):819-824.
32. Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer. 2002;94(3):832-839.
33. Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol. 2011;80(3): 460-465.
34. breakthroughcancerpain. org. APM recomendations. Association for Palliative Medicine of Great Britain and Ireland; 2009. Available from: http://www.breakthroughcancerpain.org/pain-management/apm-recommendations Accessed June 12, 2012.
35. Caraceni A, Hanks G, Kaasa S, et al; European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012; 13(2):e58-e68.
36. Virizuela JA, Escobar Y, Cassinello J, Borrega P. Treatment of cancer pain: Spanish Society of Medical Oncology (SEOM) recommendations for clinical practice. Clin Transl Oncol. 2012;14(7):499-504.
37. LeBlanc TW, Back AL. Linking palliative care and oncology practice: performance status as a common thread. J Oncol Pract. 2011;7(6): 381-382.
38. Mercadante S, Gatti A, Porzio G, et al. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin. 2012;28(6):963-968.
39. Mercadante S. Oral trasmucosal fentanyl citrate for breakthrough pain in treatment in cancer patients. Expert Opin Pharmacother. 2012;13(6):873-878.
40. Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs. 2012;72(2):181-190.